Fw: HIVandHepatitis newsletter from CROI

[Guest guest]

e-Newsletter: HIV and Hepatitis.com

Having trouble viewing this email?

Click here

Special CROI 2012 Issue

e-Newsletter for Wednesday, March 7, 2012

HIV/AIDS

CROI: Final Partners PrEP Results Confirm Efficacy of Oral Antiretrovirals for HIV Prevention

Daily, oral pre-exposure prophylaxis (PrEP) using either tenofovir (Viread) or tenofovir/emtricitabine (Truvada) was highly effective at preventing HIV infection in a large study of serodiscordant heterosexual couples in sub-Saharan Africa, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.

CROI: Hormonal Contraception May Raise HIV Risk for Women, but Uncertainty Remains

Injectable hormonal contraception may raise the risk of HIV infection for women, but it does not appear to increase the risk of HIV disease progression in women with HIV, according to findings from 2 new studies presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.

Hepatitis C

CROI: GS-7977/Ribavirin Rapidly Suppresses HCV, but Most Patients Relapse after Stopping Treatment

An interferon-free combination of the experimental polymerase inhibitor GS-7977 plus ribavirin potently and rapidly reduced hepatitis C virus (HCV) levels, but almost all patients experienced viral rebound after they stopped treatment, researchers reported Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.

CROI: New Hepatitis C Drugs in Clinical Practice

New therapies are leading to a "huge sea change" in the way infectious disease doctors are thinking about hepatitis C, Dieterich suggested at a press conference at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.

HIV/HCV Coinfection

CROI: Telaprevir and Boceprevir Improve Sustained Response Rates in HIV/HCV Coinfected Patients

Adding a first-generation HCV protease inhibitor to pegylated interferon/ribavirin dramatically increases the likelihood of 12-week sustained virological response among HIV/HCV coinfected people, researchers reported Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle.

CROI: New Hepatitis C Drugs in Clinical Practice

New therapies are leading to a "huge sea change" in the way infectious disease doctors are thinking about hepatitis C, Dieterich suggested at a press conference at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.

Forward email

This email was sent to liz@... by newsletter@... |

Update Profile/Email Address | Instant removal with SafeUnsubscribeâ„¢ | Privacy Policy.

HIVandHepatitis.com | 584 Castro Street #272 | San Francisco | CA | 94114